QQQ   358.44 (+0.12%)
AAPL   171.18 (+0.29%)
MSFT   316.03 (+0.76%)
META   301.20 (-0.91%)
GOOGL   130.81 (-1.13%)
AMZN   127.00 (+0.81%)
TSLA   249.59 (+1.30%)
NVDA   435.55 (+1.08%)
NIO   9.01 (+1.12%)
BABA   86.83 (+1.51%)
AMD   103.63 (+0.85%)
T   14.98 (-0.20%)
F   12.41 (-1.19%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.02%)
GE   110.77 (-1.40%)
DIS   80.89 (+0.95%)
AMC   7.95 (+2.05%)
PFE   33.09 (+3.12%)
PYPL   58.33 (+0.26%)
NFLX   376.80 (+0.12%)
QQQ   358.44 (+0.12%)
AAPL   171.18 (+0.29%)
MSFT   316.03 (+0.76%)
META   301.20 (-0.91%)
GOOGL   130.81 (-1.13%)
AMZN   127.00 (+0.81%)
TSLA   249.59 (+1.30%)
NVDA   435.55 (+1.08%)
NIO   9.01 (+1.12%)
BABA   86.83 (+1.51%)
AMD   103.63 (+0.85%)
T   14.98 (-0.20%)
F   12.41 (-1.19%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.02%)
GE   110.77 (-1.40%)
DIS   80.89 (+0.95%)
AMC   7.95 (+2.05%)
PFE   33.09 (+3.12%)
PYPL   58.33 (+0.26%)
NFLX   376.80 (+0.12%)
QQQ   358.44 (+0.12%)
AAPL   171.18 (+0.29%)
MSFT   316.03 (+0.76%)
META   301.20 (-0.91%)
GOOGL   130.81 (-1.13%)
AMZN   127.00 (+0.81%)
TSLA   249.59 (+1.30%)
NVDA   435.55 (+1.08%)
NIO   9.01 (+1.12%)
BABA   86.83 (+1.51%)
AMD   103.63 (+0.85%)
T   14.98 (-0.20%)
F   12.41 (-1.19%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.02%)
GE   110.77 (-1.40%)
DIS   80.89 (+0.95%)
AMC   7.95 (+2.05%)
PFE   33.09 (+3.12%)
PYPL   58.33 (+0.26%)
NFLX   376.80 (+0.12%)
QQQ   358.44 (+0.12%)
AAPL   171.18 (+0.29%)
MSFT   316.03 (+0.76%)
META   301.20 (-0.91%)
GOOGL   130.81 (-1.13%)
AMZN   127.00 (+0.81%)
TSLA   249.59 (+1.30%)
NVDA   435.55 (+1.08%)
NIO   9.01 (+1.12%)
BABA   86.83 (+1.51%)
AMD   103.63 (+0.85%)
T   14.98 (-0.20%)
F   12.41 (-1.19%)
MU   68.19 (+4.59%)
CGC   0.79 (-3.02%)
GE   110.77 (-1.40%)
DIS   80.89 (+0.95%)
AMC   7.95 (+2.05%)
PFE   33.09 (+3.12%)
PYPL   58.33 (+0.26%)
NFLX   376.80 (+0.12%)
NASDAQ:ADVM

Adverum Biotechnologies (ADVM) Stock Forecast, Price & News

$1.50
-0.03 (-1.96%)
(As of 03:00 PM ET)
Compare
Today's Range
$1.49
$1.63
50-Day Range
$1.52
$2.23
52-Week Range
$0.53
$2.34
Volume
136,979 shs
Average Volume
413,468 shs
Market Capitalization
$151.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.75

Adverum Biotechnologies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
138.1% Upside
$3.75 Price Target
Short Interest
Healthy
1.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
0.23mentions of Adverum Biotechnologies in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$9,426 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.19) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

128th out of 971 stocks

Biological Products, Except Diagnostic Industry

14th out of 158 stocks


ADVM stock logo

About Adverum Biotechnologies (NASDAQ:ADVM) Stock

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

ADVM Price History

ADVM Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Adverum Biotechnologies (ADVM) Receives a Hold from RBC Capital
See More Headlines
Receive ADVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADVM Company Calendar

Last Earnings
8/10/2023
Today
9/29/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADVM
Employees
123
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.75
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+151.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-154,540,000.00
Pretax Margin
-3,704.42%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$1.82 per share

Miscellaneous

Free Float
95,640,000
Market Cap
$150.49 million
Optionable
Optionable
Beta
0.82
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Laurent  FischerDr. Laurent Fischer (Age 59)
    Pres, CEO & Director
    Comp: $977.23k
  • Ms. Linda M. Rubinstein M.A. (Age 56)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $111.89k
  • Mr. Kishor Peter Soparkar J.D. (Age 52)
    Chief Operating Officer
    Comp: $656.96k
  • Mr. John W. Rakow J.D. (Age 66)
    Sr. VP & Gen. Counsel
    Comp: $954.24k
  • Dr. Setareh Seyedkazemi Pharm.D. (Age 49)
    Chief Devel. Officer
    Comp: $834.57k
  • Dr. R. Andrew Ramelmeier Ph.D. (Age 61)
    Chief Technology Officer
  • Dr. Brigit Riley Ph.D. (Age 45)
    Chief Scientific Officer
  • Ms. Dena House
    Sr. VP of HR, Organizational Devel. & Learning
  • Ms. Carla Fiankan
    Sr. VP of Regulatory Affairs
  • Dr. Jim Wang Ph.D.
    Chief Regulatory Officer













ADVM Stock - Frequently Asked Questions

Should I buy or sell Adverum Biotechnologies stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ADVM shares.
View ADVM analyst ratings
or view top-rated stocks.

What is Adverum Biotechnologies' stock price forecast for 2023?

4 brokerages have issued 1 year target prices for Adverum Biotechnologies' shares. Their ADVM share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $3.75 in the next year. This suggests a possible upside of 151.7% from the stock's current price.
View analysts price targets for ADVM
or view top-rated stocks among Wall Street analysts.

How have ADVM shares performed in 2023?

Adverum Biotechnologies' stock was trading at $0.5795 at the beginning of the year. Since then, ADVM shares have increased by 157.1% and is now trading at $1.4901.
View the best growth stocks for 2023 here
.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,340,000 shares, an increase of 20.7% from the August 31st total of 1,110,000 shares. Based on an average daily trading volume, of 438,300 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.5% of the shares of the company are short sold.
View Adverum Biotechnologies' Short Interest
.

When is Adverum Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our ADVM earnings forecast
.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) announced its earnings results on Thursday, August, 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.01.

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees.

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $1.49.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies (NASDAQ:ADVM) has a market capitalization of $150.49 million and generates $7.50 million in revenue each year. The biotechnology company earns $-154,540,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

The company employs 123 workers across the globe.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.adverum.com. The biotechnology company can be reached via phone at (650) 656-9323, via email at mlacy@adverum.com, or via fax at 650-329-8151.

This page (NASDAQ:ADVM) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -